Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (email | Twitter) and we will feature it here each Friday.
Connelly departs Pulmatrix, Clarke takes company helm as new CEO
Over at Pulmatrix, longtime CEO Robert Connelly bid farewell and left his post at the Massachusetts biotech. His next destination: WikiCell Designs, a startup that makes edible food packaging. With Connelly gone, Pulmatrix Chief Scientific Officer Robert Clarke moves up the C-level ladder and takes on the role of CEO. With the top post filled, Pulmatrix is focusing on generating a new round of funding to advance its COPD drug, PUR118, into Phase II. Story | Pulmatrix release | WikiCell release
|
Robert Connelly--Pulmatrix
Biotech
> Civitas Therapeutics appointed Bryan Stuart as chief business officer. Release
> Susan Akers-Smith was promoted to vice president of early phase oncology development at INC Research. Release
> VaxInnate welcomed two new executives to its management team: Christine Mayer as vice president of business development and Katalin Abraham as vice president of regulatory affairs. Release
> Aileron Therapeutics appointed Dr. Hubert Chen as vice president of clinical development. Release
> NexDx welcomed Zachary Hornby and Kurt Krummel to its management team. Hornby will serve as vice president of corporate development, while Krummel will be director of molecular diagnostics and assay development. Release
> Dr. Robert Martell joined Tesaro ($TSRO) as chief medical officer. Release
> Navidea Biopharmaceuticals welcomed Dr. Cornelia Reininger to the role of chief medical officer. Release
Pharma
> With Robert Armitage retiring from Eli Lilly ($LLY), Michael Harrington became senior vice president and general counsel. Release
> Steven Gillis will join the board of directors at Shire ($SHPG) effective Oct. 1. Release
Medical Devices
> Sonitus Medical named Mike Favet as chief operating officer and Jeff Mack as chief financial officer. Release